vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and RMR GROUP INC. (RMR). Click either name above to swap in a different company.

RMR GROUP INC. is the larger business by last-quarter revenue ($66.7M vs $37.2M, roughly 1.8× GYRE THERAPEUTICS, INC.). RMR GROUP INC. runs the higher net margin — 18.3% vs -3.7%, a 21.9% gap on every dollar of revenue. On growth, RMR GROUP INC. posted the faster year-over-year revenue change (40.8% vs 33.4%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

RMR Group Inc. is a U.S.-headquartered alternative asset management firm specializing in real estate and real estate-related investments. It operates across commercial property, residential real estate, and infrastructure segments, serving institutional investors, high-net-worth individuals, and retail clients across key global markets.

GYRE vs RMR — Head-to-Head

Bigger by revenue
RMR
RMR
1.8× larger
RMR
$66.7M
$37.2M
GYRE
Growing faster (revenue YoY)
RMR
RMR
+7.3% gap
RMR
40.8%
33.4%
GYRE
Higher net margin
RMR
RMR
21.9% more per $
RMR
18.3%
-3.7%
GYRE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
GYRE
GYRE
RMR
RMR
Revenue
$37.2M
$66.7M
Net Profit
$-1.4M
$12.2M
Gross Margin
95.3%
Operating Margin
0.3%
48.1%
Net Margin
-3.7%
18.3%
Revenue YoY
33.4%
40.8%
Net Profit YoY
-340.1%
91.1%
EPS (diluted)
$-0.01
$0.71

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
RMR
RMR
Q4 25
$37.2M
$66.7M
Q3 25
$30.6M
Q2 25
$26.8M
Q1 25
$22.1M
Q4 24
$27.9M
Q3 24
$25.5M
Q2 24
$25.2M
Q1 24
$27.2M
Net Profit
GYRE
GYRE
RMR
RMR
Q4 25
$-1.4M
$12.2M
Q3 25
$5.9M
Q2 25
$1.6M
Q1 25
$3.7M
Q4 24
$569.0K
Q3 24
$2.9M
Q2 24
$4.5M
Q1 24
$9.9M
Gross Margin
GYRE
GYRE
RMR
RMR
Q4 25
95.3%
Q3 25
94.7%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
RMR
RMR
Q4 25
0.3%
48.1%
Q3 25
22.7%
Q2 25
8.1%
Q1 25
10.3%
Q4 24
2.4%
Q3 24
16.6%
Q2 24
12.7%
Q1 24
29.7%
Net Margin
GYRE
GYRE
RMR
RMR
Q4 25
-3.7%
18.3%
Q3 25
19.4%
Q2 25
5.9%
Q1 25
16.9%
Q4 24
2.0%
Q3 24
11.2%
Q2 24
18.0%
Q1 24
36.6%
EPS (diluted)
GYRE
GYRE
RMR
RMR
Q4 25
$-0.01
$0.71
Q3 25
$0.03
Q2 25
$0.00
Q1 25
$0.00
Q4 24
$0.00
Q3 24
$0.01
Q2 24
$0.01
Q1 24
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
RMR
RMR
Cash + ST InvestmentsLiquidity on hand
$52.4M
$49.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$232.7M
Total Assets
$166.1M
$687.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
RMR
RMR
Q4 25
$52.4M
$49.3M
Q3 25
$60.0M
Q2 25
$54.4M
Q1 25
$29.9M
Q4 24
$26.7M
Q3 24
$25.1M
Q2 24
$25.1M
Q1 24
$37.4M
Stockholders' Equity
GYRE
GYRE
RMR
RMR
Q4 25
$106.0M
$232.7M
Q3 25
$101.9M
Q2 25
$92.0M
Q1 25
$68.1M
Q4 24
$63.3M
Q3 24
$63.2M
Q2 24
$60.4M
Q1 24
$56.6M
Total Assets
GYRE
GYRE
RMR
RMR
Q4 25
$166.1M
$687.1M
Q3 25
$159.4M
Q2 25
$152.6M
Q1 25
$129.8M
Q4 24
$125.4M
Q3 24
$125.2M
Q2 24
$120.9M
Q1 24
$122.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
RMR
RMR
Operating Cash FlowLast quarter
$-5.6M
$10.7M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
RMR
RMR
Q4 25
$-5.6M
$10.7M
Q3 25
$4.7M
Q2 25
$2.1M
Q1 25
$-129.0K
Q4 24
$-2.8M
Q3 24
$1.7M
Q2 24
$-5.5M
Q1 24
$2.9M
Free Cash Flow
GYRE
GYRE
RMR
RMR
Q4 25
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-251.0K
Q4 24
$-2.8M
Q3 24
$1.0M
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
RMR
RMR
Q4 25
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
-1.1%
Q4 24
-10.1%
Q3 24
4.1%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
RMR
RMR
Q4 25
0.4%
Q3 25
2.2%
Q2 25
1.0%
Q1 25
0.6%
Q4 24
0.2%
Q3 24
2.7%
Q2 24
5.8%
Q1 24
0.9%
Cash Conversion
GYRE
GYRE
RMR
RMR
Q4 25
0.88×
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

RMR
RMR

Management Service Incentive$23.6M35%
Industrial Logistics Properties Trust$15.1M23%
Managed Private Real Estate Capital$11.1M17%
Office Properties Income Trust$5.6M8%
Other Private Entities$5.3M8%
RMR Residential$3.4M5%
Sonesta International Hotels Corporation$2.1M3%
Investment Advisory Management And Administrative Service$1.2M2%

Related Comparisons